



## Press Release

September 5, 2018

---

# Strides receives USFDA approval for Potassium Chloride Extended Release Tablets Second approval from the Extended Release portfolio

Product approval from flagship facility at Bangalore  
To be launched immediately by Strides Pharma Inc. in the US markets

---

**Bangalore, September 5, 2018** Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for **Potassium Chloride Extended Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg)** from the United States Food & Drug Administration (US FDA). This is the second Extended Release product approval for Strides and the company has a strong pipeline of products leveraging its capability in the Extended Release delivery technology. Potassium Chloride Extended-Release tablets is a generic version of Klor-Con Extended Release Tablets of Upsher-Smith and Strides is the first Indian generic company to receive this approval.

According to IQVIA MAT data, the US market for **Potassium Chloride Extended Release Tablets** is approximately US\$ 60 Mn. The product will be manufactured at the company's facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.

The company has 78 cumulative ANDA filings with USFDA of which 52 ANDAs have been approved as of date and 26 are pending approval.

### About Potassium Chloride Extended Release Tablets

For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis.

Extended release tablet is formulated in such a way that the drug is released slowly over time. This has the advantage of taking pills less often and fewer side effects, as the levels of the drug in the body are more consistent.

### About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 facilities for Regulated Markets and 2 facilities for the Emerging Markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com)

### **For further information, please contact:**

#### Strides

Badree Komandur,  
Executive Director - Finance  
+91 80 6784 0747

#### Investor Relations:

Kannan. N: +91 98450 54745  
Vikesh Kumar: +91 80 6784 0827  
Sandeep Baid : +91 80 6784 0791

#### Strides Pharma Science Limited

(Formerly Strides Shasun Limited)  
CIN : L24230MH1990PLC057062  
Regd. Office: 201, 'Devavrata', Sector - 17,  
Vashi, Navi Mumbai - 400 703  
Corp. Office: Strides House,  
Bannerghatta Road, Bangalore - 560076  
Email: [investors@strides.com](mailto:investors@strides.com)

#### PR Consultancy

Fortuna PR  
K Srinivas Reddy: +91 90005 27213  
[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

K Priya: +91 95354 25418  
[priya@fortunapr.com](mailto:priya@fortunapr.com)